Zyprexa

Worldwide, Other products fared better.

Sales of osteoporosis medication Forteo increased 59 percent to $118 million, erectile dysfunction drug Cialis increased 38 percent and four diabetes drugs climbed 11 percent to a combined $750 million.

"Lilly is determined to be a leader in diabetes care," said Jim Ward, Lilly's executive director of investor relations.

The company is bulking up its marketing and manufacturing for the insulin medication Humalog.

Excluding certain charges in 2004 and 2005, as well as stock-option expensing in 2004, Lilly's earnings for the latest quarter would have risen to 80 cents per share, compared with 69 cents per share in the prior year.

Analysts polled by Thomson Financial expected earnings of 78 cents per share on $3.9 billion in sales.

For the full year, the company earned $1.98 billion, or $1.81 per share, versus $1.81 billion, or $1.66 a share, a year ago.

Sales rose to $14.65 billion from $13.86 billion.

Eli Lilly said it expects 2006 earnings of 73 cents to 75 cents per share for the first quarter and $3.10 to $3.20 per share for the year, with full-year sales up 7 percent to 9 percent.

Analysts forecast first-quarter profit of 75 cents per share, as well as full-year earnings of ...

Worldwide, Other products fared better.

Sales of osteoporosis medication Forteo increased 59 percent to $118 million, erectile dysfunction drug Cialis increased 38 percent and four diabetes drugs climbed 11 percent to a combined $750 million.

"Lilly is determined to be a leader in diabetes care," said Jim Ward, Lilly's executive director of investor relations.

The company is bulking up its marketing and manufacturing for the insulin medication Humalog.

Excluding certain charges in 2004 and 2005, as well as stock-option expensing in 2004, Lilly's earnings for the latest quarter would have risen to 80 cents per share, compared with 69 cents per share in the prior year.

Analysts polled by Thomson Financial expected earnings of 78 cents per share on $3.9 billion in sales.

For the full year, the company earned $1.98 billion, or $1.81 per share, versus $1.81 billion, or $1.66 a share, a year ago.

Sales rose to $14.65 billion from $13.86 billion.

Eli Lilly said it expects 2006 earnings of 73 cents to 75 cents per share for the first quarter and $3.10 to $3.20 per share for the year, with full-year sales up 7 percent to 9 percent.

Analysts forecast first-quarter profit of 75 cents per share, as well as full-year earnings of ...